Maxim Sports Nutrition fills sales and marketing role
DENVER — Maxim Sports Nutrition on Friday announced the addition of Robin Barsantee as the company’s director of sales and marketing. This latest hire further solidifies Maxim Sports Nutrition commitment to the U.S. and to growing brand awareness, the company stated.
Barsantee will support both the sales and marketing strategies to increase brand awareness and to continue the momentum of the company’s growth since introducing Maxim to the U.S. markets earlier in the year. Barsantee will be responsible for implementing sales strategies to build and grow current and potential revenue channels and develop and execute an in-store education strategy not only for consumers but for sales associates, as well.
With more than 15 years of industry experience in sales, marketing and event management, Barsantee will develop plans to help drive the sports specialty business in the United States. Before joining Maxim Nutrition Systems, Barsantee held positions at Titleist, Polar, Zoot, Timex and recently at SKINS, as the national sales director.
Barsantee brings a unique perspective to Maxim Sports Nutrition as a professional golfer, an avid long distance endurance athlete and as a competitive age group triathlete who has completed nine full Ironman competitions, Maxim added.
Maxim includes a proprietary blend of European maltodextrin, a non-GMO form of sustained energy. Maxim provides a complete range of electrolytes and essential vitamins from a single source.
No comments found
GSK’s new Flonase already a top allergy seller
NEW YORK — The true allergy tsunami this year is GlaxoSmithKline's new allergy remedy Flonase, which has already generated almost $100 million in its first 16 weeks on shelf and rocketed to the top of the cough/cold/sinus/allergy liquids brand list as sold across total U.S. multi-outlet, according to IRI figures.
That $100 million lift to GSK's Consumer Healthcare business accounted for half of the division's 24% growth in quarterly sales, Simon Dingemans, GSK CFO, recently told analysts earlier in May.
For the 12 weeks ended May 17, Flonase sales were more than double those of competitor corticosteroid nasal spray Nasacort Allergy 24HR and the GSK brand is not likely to face store brand competition anytime soon.
Perrigo president and CEO Joseph Papa told analysts in February, at the time Flonase launched, that he was unsure GSK could maintain its three-year exclusivity on Flonase beyond specific claims for allergy eyes. However, Perrigo had no immediate plans to introduce a store brand Flonase.
“As to how it’s going to play out between that time, whether or not we want to go to the market with Flonase prior to the expiration of the allergic eye data … that’s unclear at this time,” he said. “So right now, we are not planning for our Flonase product to get to the market [in] 2015," he added. "We are still working with the regulatory side.”
Nice article…Flonase market is booming now. You can get its Market Manufactures and Key Statistics Analysis @ https://goo.gl/4GMCFQ
GoJo increases manufacturing capacity on anticipated growth
AKRON, Ohio – GoJo announced Friday that it has agreed to lease 1.3 million square feet of space in Wooster, Ohio, which will be used to expand manufacturing and distribution operations. The GoJo Wooster Campus is in addition to the GoJo headquarters in Akron, Ohio, manufacturing and distribution in Cuyahoga Falls, Ohio, and operations worldwide including those in the United Kingdom, Australia, Brazil, Canada, Japan, Mexico and France.
"GoJo expansion has been consistent overtime as our business has grown," said Mark Lerner, GoJo president and COO. "We are building capacity in Wooster to accommodate anticipated future growth. We look forward to creating new jobs here for Northeast Ohioans and maintaining our commitment to helping this region grow."
It will take the next six months to a year to update the infrastructure of the facilities and begin operations in Wooster, the company reported.
No comments found
Loading Post Please Wait...